



Loss-of-function variants affecting the STAGA complex component *SUPT7L* cause a developmental disorder with generalized lipodystrophy

Johannes Kopp^{1,2,3} · Leonard A. Koch¹ · Hristiana Lyubenova^{1,2} · Oliver Küchler^{1,4} · Manuel Holtgrewe⁵ · Andranik Ivanov⁵ · Christele Dubourg^{6,7} · Erika Launay⁸ · Sebastian Brachs^{9,10} · Stefan Mundlos^{1,2} · Nadja Ehmke^{1,11} · Dominik Seelow^{1,4} · Mélanie Fradin^{12,13} · Uwe Kornak^{1,2,14} · Björn Fischer-Zirnsak^{1,2}

Received: 30 November 2023 / Accepted: 11 March 2024
© The Author(s) 2024

Abstract

Generalized lipodystrophy is a feature of various hereditary disorders, often leading to a progeroid appearance. In the present study we identified a missense and a frameshift variant in a compound heterozygous state in *SUPT7L* in a boy with intrauterine growth retardation, generalized lipodystrophy, and additional progeroid features. *SUPT7L* encodes a component of the transcriptional coactivator complex STAGA. By transcriptome sequencing, we showed the predicted missense variant to cause aberrant splicing, leading to exon truncation and thereby to a complete absence of *SUPT7L* in dermal fibroblasts. In addition, we found altered expression of genes encoding DNA repair pathway components. This pathway was further investigated and an increased rate of DNA damage was detected in proband-derived fibroblasts and genome-edited HeLa cells. Finally, we performed transient overexpression of wildtype *SUPT7L* in both cellular systems, which normalizes the number of DNA damage events. Our findings suggest *SUPT7L* as a novel disease gene and underline the link between genome instability and progeroid phenotypes.

Keywords Lipodystrophy · Wiedemann-Rautenstrauch syndrome · *SUPT7L* · Aberrant splicing · Progeroid disorder · STAGA complex

Introduction

Lipodystrophy, the partial or generalized loss of adipose tissue, is a clinical sign in several rare monogenic disorders and is often leading to a progeroid phenotype (Nolis 2014; Jéru 2021). The molecular basis of these conditions is heterogeneous and ranges from alterations of the extracellular matrix to processes regulating DNA repair and transcription (Jéru 2021). The best known disease with progeroid features and a systemic lipodystrophy is Hutchinson-Gilford Progeria syndrome (HGPS; MIM: 176670) due to aberrant splicing of pre-lamin A causing alterations of the nuclear envelope (Eriksson et al. 2003; De Sandre-Giovannoli et al. 2003). Other conditions like Werner syndrome (WRN; MIM: 277700) and the group

of Cockayne syndrome entities (CS; MIM: 216400) affect DNA repair and transcriptional mechanisms (Henning et al. 1995; Yu et al. 1996). Another disorder with impaired transcription is Wiedemann-Rautenstrauch syndrome (WDRS; MIM: 264090), an ultra-rare autosomal recessive neonatal progeroid syndrome. WDRS is caused by variants in the catalytic domains of RNA polymerase 3 subunits *POLR3A* or *POLR3B*, which hinder the synthesis of small RNAs (Sepehri and Hernandez 1997; Lessel et al. 2018; Paolacci et al. 2018; Wambach et al. 2018; Wu et al. 2021). Transcriptional regulation processes are important for regulating gene activity and for processing transcripts in a cell type- and tissue-dependent manner. Mostly, these processes depend on the interplay of several multi-protein complexes performing different functions (Thomas and Chiang 2006). One such protein complex is the human SPT3-TAF-GCN5 acetylase (STAGA) complex, a nuclear localized multiprotein complex playing a role in various intracellular pathways (Zhao et al. 2008;

Uwe Kornak and Björn Fischer-Zirnsak contributed equally to this work.

Extended author information available on the last page of the article

Nagy et al. 2009; Tan et al. 2014; Hirsch et al. 2015), such as splicing, transcription factor binding (Liu et al. 2003; Zhang et al. 2014), and DNA repair (Martinez et al. 2001; Liu et al. 2008; Gamper and Roeder 2008; Gamper et al. 2009; Switonski et al. 2021).

Here we report on the identification of compound heterozygous variants in *SUPT7L*, encoding a component of the STAGA complex, in an individual with generalized lipodystrophy, cataracts and a neonatal tooth, sharing features with Wiedemann-Rautenstrauch syndrome and other progeroid disorders.

Materials and methods

Affected individual

Peripheral blood samples were taken from the affected individual and his parents. In addition, a skin biopsy was obtained from the affected individual and dermal fibroblasts were cultivated according to standard procedures.

Genome sequencing

Genome sequencing was performed on the DNA samples from individuals I-1, I-2 and II-1. Libraries were prepared with the DNA tagmentation based library preparation kit (Illumina) without PCR, with 500 ng gDNA input. Library preparation was followed by clean up and/or size selection using SPRI beads (Beckman Coulter Genomics). After library quantification (Qubit, Life Technologies) and validation (Agilent Tape Station), equimolar amounts of library were pooled. The library pools were quantified using the Peqlab KAPA Library Quantification Kit and the Applied Biosystems 7900HT Sequence Detection System and then sequenced on an Illumina NovaSeq6000 sequencing instrument with a paired-end 2 × 150 bp protocol (Target coverage 300x or 1200 Gb per sample). Sequence reads were mapped to the genome version GRCh37 (UCSC hg19) with the Burrows-Wheeler Aligner (BWA MEM). Single-nucleotide variants and short indels were called with the Genome Analysis Toolkit (GATK) according to the GATK Best Practices (McKenna et al. 2010; DePristo et al. 2011). We used Janovar (Jäger et al. 2014) for variant annotation, and Varfish for filtering and further data analysis as described previously (Holtgrewe et al. 2020).

Sanger sequencing

Sanger sequencing was performed to validate the variants in *SUPT7L* in DNA samples from the proband and his parents. Exon 2 and 3 of *SUPT7L* were amplified using the

FIREPol Mastermix (SOLIS BIODYNE, Tartu, Estonia) in a ProFlex PCR System (Thermo Fisher Scientific, Dreieich, Germany). Sequencing was performed using BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific, Dreieich, Germany) and electrophoresis was carried out on an ABI 3730 DNA Analyzer (Thermo Fisher Scientific, Dreieich, Germany). All primer sequences are listed in Supplementary Table 1.

Cell culture

Dermal fibroblasts and HeLa cell line were cultured in DMEM (4.5 g/l glucose, Gibco, Thermo Fisher Scientific, Dreieich, Germany) with 10% fetal calf serum (Gibco, Thermo Fisher Scientific, Dreieich, Germany), 1% Ultra-Glutamine (Lonza, Basel, Switzerland) and 1% penicillin/streptomycin (Lonza, Basel, Switzerland) at 37°C and 5% CO₂.

RNA extraction and cDNA synthesis

Cells were lysed in Trizol (Thermo Fisher Scientific, Dreieich, Germany) and total RNA was extracted using the Direct-Zol RNA Miniprep kit (Zymo Research, Freiburg, Germany). cDNA was transcribed using the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Dreieich, Germany).

Qualitative RT-PCR

cDNAs were amplified with primers in exon 2 and 4 of *SUPT7L* using the FIREPol Mastermix (SOLIS BIODYNE, Tartu, Estonia) in a ProFlex PCR System (Thermo Fisher Scientific, Dreieich, Germany). After Agarose-Gel-Electrophoresis a gel extraction of the amplified fragments S1 of II-1 was performed using the QIAquick Gel Extraction Kit (Qiagen, Venlo, Netherlands). Sequencing of these products were performed as described above. All primer sequences are listed in Supplementary Table 1.

Quantitative RT-PCR

Quantitative PCR was performed on cDNA samples (generated as described above) and carried out using Eva Green (Solis BioDyne, Tartu, Estonia) on a QuantStudio 03 system (Thermo Fisher Scientific, Dreieich, Germany) using two different primer pairs. All primer sequences are listed in Supplementary Table 1.

RNA sequencing and bioinformatics

We performed a poly-A (pA) enrichment from total RNA preparations (II-1 (three technical replicates) and three unaffected controls). Libraries were prepared using the Illumina Stranded TruSeq RNA sample preparation protocol. Library preparation started with 500 ng total RNA. After poly-A selection (using poly-T oligo-attached magnetic beads), mRNA was purified and fragmented using divalent cations under elevated temperature. The RNA fragments underwent reverse transcription using random primers. This was followed by second strand cDNA synthesis with DNA Polymerase I and RNase H. After end repair and A-tailing, indexing adapters were ligated. The products were then purified and amplified (15 PCR cycles) to create the final cDNA libraries. After library validation and quantification (Agilent Tape Station), equimolar amounts of library were pooled. The pools were quantified by using the Peqlab KAPA Library Quantification Kit and the Applied Biosystems 7900HT Sequence Detection System. The pools were sequenced on an Illumina NovaSeq6000 sequencing instrument (Illumina, San Diego, CA, USA) with a PE100 protocol. 60–70 million sequence reads were generated. RNA-Seq reads were mapped to the human genome (GRCh38.p7) with STAR version-2.7.9a (Dobin et al. 2013). Reads were assigned to genes using FeatureCounts SUBREAD version-v2.0.1 (Liao et al. 2014). For the differential expression analyses we used DESeq2 version-1.34.0 (Love et al. 2014). The gene set enrichment analysis was carried out using CERNO algorithm from R tmod package version-0.46.2 (Zyla et al. 2019). All results are listed in Supplementary Table 2.

Immunoblot

Proteins were extracted in RIPA buffer (150 mM NaCl, 50 mM Tris, 5 mM EDTA, 1% Triton X-100, 0.25% Desoxycholate, 5% SDS) containing protease inhibitor (cOmplete, Roche, Basel, Switzerland). 20 µg of protein per lane was separated by SDS-PAGE, transferred to nitrocellulose membrane and probed with primary antibodies. Immunoblot staining was performed for SUPT7L (rabbit anti-SUPT7L; 25606-1-AP, Proteintech, Rosemont, Illinois, USA), SUPT3H (mouse anti-SPT3, #sc-101157, Santa Cruz Biotechnology, Dallas, Texas), TAF10 (rabbit anti-TAF10, ab263967, Abcam, Cambridge, UK), Lamin A/C (mouse anti-LAMIN A/C; NB100-74451, Novusbio, Centennial, Colorado, USA) and GAPDH (anti-GAPDH, #AM4300, ThermoFisher, Massachusetts, USA). Membranes were incubated with IRDye-/ HRP-conjugated secondary antibodies. Signals were detected with OdysseyFc Imaging System and densitometric quantification was performed using

Image Studio (LI-COR Biosciences, Lincoln, Nebraska USA).

Immunofluorescence

Dermal fibroblasts were grown on glass coverslips overnight. Fixation was performed for 10 min in 4% paraformaldehyde at room temperature. The cells were permeabilized using 0.4% Triton X-100 in 3% BSA in 1x PBS for 10 min at room temperature. Immunofluorescence staining was performed for SUPT7L (rabbit anti-SUPT7L; 25606-1-AP, Proteintech, Rosemont, Illinois, USA), LAMIN A/C (mouse anti-LAMIN A/C; NB100-74451, Novusbio, Centennial, Colorado, USA), γ H2A.X (mouse anti-pH2A.X (Ser139)(#05-636-I, Merck, Darmstadt, Germany) and turbo-GFP (rabbit anti-turboGFP (#TA150071 Origene, Rockville, Maryland, USA) overnight in 3% BSA in 1x PBS. Secondary antibody staining was performed using anti-mouse IgG Alexa Fluor 488 (#A21202, Invitrogen Waltham, Massachusetts USA) and anti-rabbit IgG Alexa Fluor 555 (#A21572, Invitrogen, Waltham, Massachusetts USA) for 1 h in 1x PBS at room temperature. DNA was stained by DAPI and cells were mounted in Fluoromount G (Biozol, Eching, Germany). Pictures were taken using a LSM700 (Zeiss, Oberkochen, Germany). Each experiment was performed three times.

Cloning of CRISPR/Cas9 plasmid and generation of SUPT7L knockout HeLa cells

The single guide RNA (sgRNA) targeting the third exon of human *SUPT7L* was designed using the Benchling sgRNA design tool (www.benchling.com) and was selected based on its predicted on- and off-target scores. The sgRNA was then cloned into the PX459 vector from Addgene (#62,988) as previously described (Ran et al. 2013). The final vector was transfected using jetPEI (Polyplus, Illkirch, France) into HeLa EM2-11th cells (Weidenfeld et al. 2009) and 48 h post transfection positive clone selection was initiated with 1.5 µg/ml Puromycin (Thermo Fisher Scientific, Dreieich, Germany). Puromycin-selected single cell clones were expanded and validated by Sanger sequencing. One cell clone carrying a single nucleotide deletion 4 base pairs upstream of the PAM sequence (c.226delC) was selected and further characterized. The deletion causes a frameshift and premature stop codon leading to the gene knockout (KO) (Supplementary Fig. 1).

Cell proliferation assay

Cell proliferation was measured using a WST-1 proliferation assay (Roche, Basel, Switzerland) according to

manufacturer's instructions. In brief, sextuplicates of each cell line (1×10^4 cells/well) were seeded in microtiter plates in 100 μ l medium in a humidified atmosphere (37 °C, 5% CO₂) for 24 h. Then, 10 μ l/well Cell Proliferation Reagent WST-1 were added and incubated for another 2 h. Before measurement, plates were shaken for 1 min and OD/absorbance was determined at 450 nm with 690 nm as reference against blank as background control on a microtiter plate reader (Infinite 200 pro, Tecan).

Analysis of DNA damage

For analyzing DNA damage in dermal fibroblasts (II-1 and unaffected controls) and HeLa cells (WT and SUPT7L-KO), cells were seeded on glass coverslips and handled as described above. γ H2A.X (Ser139), a marker for DNA damage (Paull et al. 2000), was stained in the cells and the number of cells with more than six foci of γ H2A.X in the nucleus was quantified using immunofluorescence analyses. At least 100 cells per sample were counted and the experiment was performed three times.

Rescue of the DNA damage phenotype

Dermal fibroblasts from the affected individual, unaffected controls and HeLa cells (WT and SUPT7L-KO) were transfected with 2 μ g of pCMV6-AC-GFP+SUPT7L-WT (NM_014860.3, Origene) using the Amaxa Nucleofector® 2b (Lonza, Basel, Switzerland) according to manufacturer's instructions. Immunofluorescence staining of turboGFP and γ H2X.A was performed as described above. At least 100 transfected and untransfected cells per sample were counted and the experiment was performed three times.

Statistical analysis

Statistical analyses were performed in Prism (GraphPad Prism 8.3) using the two-way analysis of variance (ANOVA) or students t-test. Figures were designed using Inkscape.

Results

Clinical description

The affected individual II-1 is the child of healthy, unrelated parents from France. During pregnancy, intrauterine growth retardation was observed within the 3rd trimester. He was born at 36+4 weeks of gestation with Apgar scores 9/10/10. Birth weight was 2090 g (-2.0 SD), length was 42 cm (-3.1 SD), and head circumference (OFC) was 33 cm (-0.8 SD). Generalized lipodystrophy leading to thinned skin with

visible subcutaneous veins was noted neonatally as well as a triangular face with prominent forehead, downsloping palpebral fissures, hypertelorism, deep set ears, sparse hair and eyebrows and congenital cataracts (Fig. 1A). Remarkably, he had a neonatal tooth and an inguinal hernia, which was corrected by surgery. His cerebral MRI was unremarkable, while his echocardiography showed slight pericardial effusion without cardiac malformation. At three months of age he had achieved head control but other motor developmental milestones were delayed and he started walking at four years of age.

Follow up at four years of age revealed a weight of 10.7 kg (-3.8 SD), a height of 87 cm (-4 SD) and an OFC of 49 cm (-1.7 SD). In addition, he presented with an increased muscle tone and camptodactyly of the left middle finger, which was surgically corrected. His anterior fontanel was still wide open. The last follow up at six years of age revealed a weight of 14.8 kg (-3.1 SD), a height of 96 cm (-4.4 SD) and an OFC of 49 cm (-2.4 SD). All growth parameters were continuously reduced. The OFC stagnation indicates a secondary microcephaly (Woods 2004). After loss of the neonatal tooth dentition was normal. He had a prominent abdomen with an umbilical hernia. Abdominal ultrasound revealed a progressive hepatomegaly and a renal asymmetry. He made poor eye contact, had developed no language and was in general severely developmentally delayed. Due to the intrauterine onset of the phenotype it belongs to the group of a congenital segmental progeroid disorder (Lessel and Kubisch 2019). Among them, several differential diagnoses such as Berardinelli-Seip congenital lipodystrophy (CGL1-4; MIM: 608594, 279700, 612526 and 613327), Fontaine progeroid syndrome (FPS; MIM: 612289) or Wiedemann-Rautenstrauch syndrome (WDRS, MIM 264090) were discussed, however; none of these conditions were completely in line with the complex of symptoms observed in individual II-1 (Supplementary Table 3).

Laboratory investigations revealed normal values for creatine kinase and hepatic enzymes (ASAT, ALAT) at birth, which were elevated twofold at 10 months of age. Investigation of lipid values revealed slightly elevated total triglycerides (3.36 mmol/l; normal ($N < 2.26$ mmol/l)). His cholesterol values were normal, however, his leptin levels were reduced to $< 0.2 \mu\text{g/l}$ ($N > 0.35 \mu\text{g/l}$). He presented with hypothyroidism, which was successfully treated by L-thyroxin supplementation. His differential blood count showed hyperleukocytosis with polynuclear neutrophils and low platelet counts. At 4 years of age triglycerides were slightly elevated (2.41 mmol/l; $N < 2.26$ mmol/l). Platelets were still low at $101 \times 10^9/l$ ($N > 193 \times 10^9/l$). Genetic analysis by array-CGH and clinical exome sequencing revealed no pathogenic variants in known disease genes explaining this combination of symptoms.




Fig. 1 Clinical and genetic characterization of proband II-1. (A) Facial appearance of the affected individual II-1 postnatal, and with 1 month, 7 months, and 6 years. Note, the thin skin leading to visibility of his subcutaneous veins and generalized lipodystrophy. (B) We detected the variants c.80G>A and c.255_258dup in *SUPT7L* in a heterozygous state in the parents (I-1 and I-2) and in a compound heterozygous state in the index patient II-1

Disease gene identification

To decipher the genetic basis of the observed phenotype we performed trio-genome sequencing (GS) of the affected individual and his parents. Variants were evaluated using the Varfish platform (Holtgrewe et al. 2020). We assumed an autosomal recessive mode of inheritance. Initially, we tested

genes associated with different forms of lipodystrophy from Genomics England PanelApp (Lipodystrophy - childhood onset (Version 4.50); ID: R158) and all candidates listed in Supplementary Table 4. to investigate whether a variant affecting a known disease gene was initially missed. We could not find any variant explaining the observed phenotype in line with the negative result from clinical exome sequencing.

Next, we performed genome-wide filtering for rare homozygous or compound heterozygous variants. In addition, we tested for *de novo* variants in case the assumption of an autosomal recessive mode was incorrect. This approach revealed two heterozygous variants in *SUPT7L* (NM_014860.3).

The first variant c.80G>A is predicted to substitute an arginine at position 27 in the *SUPT7L* polypeptide to




Fig. 2 Consequences of the *SUPT7L* variants on mRNA level. **(A)** Transcriptome sequencing data from the proband's fibroblasts and a control. IGV alignment representing exon 2–3 of *SUPT7L*. In II-1 the duplication c.255_258dup is visible in approximately 50% of the reads (purple marks and boxes). The heterozygous variant c.80G>A was not detectable in any read, however split reads fusing exon 2 with a position within exon 3 (blue lines) indicating another *SUPT7L* isoform (S1) due to aberrant splicing. In addition, clipped reads showing sequence belonging to exon 2 were detectable (Blue boxes) **(B)** RT-PCR of *SUPT7L* exon 2 to 4 resulted in two products. The upper band represents the canonical splice product while the lower band confirmed the aberrant splice product S1 (in red) in II-1. **(C)** Schematic illustration of *SUPT7L* exons 2–4 with positions of the causative variants and the resulting aberrant splicing. Primer positions used for RT-PCR (in C) are indicated as blue boxes. Red boxes indicate alterations of *SUPT7L* mRNA compared to control

a glutamine. This alteration is not uniformly assessed as pathogenic by different tools: MutationTaster2 (Disease causing) (Schwarz et al. 2014), Polyphen 2 (Probably damaging) (Adzhubei et al. 2013) and CADD score: 32 (Kircher et al. 2014). It was only found in a heterozygous state in gnomAD (version v4.0.0) (<https://gnomad.broadinstitute.org/>) in ten individuals from different ancestry groups (MAF: 0.000006196). Besides the predicted amino acid change, this variant might form a cryptic splice acceptor site according to VarSeak (Supplementary Fig. 2A). MobiDetails reported the highest propensity for abnormal splicing for adipose tissue (AbSplice max. tissue score 0.04) (Baux et al. 2021; Wagner et al. 2023). We found this alteration to be inherited from the clinically unaffected mother (I-2) (Fig. 1B).

The second variant c.255_258dup was detected in a heterozygous state and leads to a frameshift and a premature termination codon (PTC) after 12 additional codons p.(Asn87Profs*12). This paternally inherited variant was only found in a heterozygous state in gnomAD (version v4.0.0)(MAF: 0.00001573) and was predicted to be probably damaging by MutationTaster (Probably damaging)(Fig. 1B).

Both detected variants are extremely rare and have never been observed in a homozygous state. A closer inspection of the *SUPT7L* locus in gnomAD revealed an absence of homozygous loss-of-function (LoF) variants (Karczewski et al. 2020). In addition, the observed number of single nucleotide variants slightly differs from the expected number, however, the loss-of-function observed/expected upper bound fraction (LOEUF) value is 0.618, indicating that this gene is not sensitive for haploinsufficiency. This is in line with the heterozygous parents showing no signs of the disease. Neither through platforms such as GeneMatcher (Sobreira et al. 2015) nor personal communication with cooperation partners we were able to identify any other individual with homozygous or compound heterozygous variants in *SUPT7L*.

Functional consequences of the nucleotide substitutions

In parallel to trio-GS, we performed poly A-enriched transcriptome sequencing of three technical replicates from the affected individual's dermal fibroblasts and four matched controls. We found the variant c.255_258dup in approximately half of the sequence reads while the variant c.80G>A was not found in the transcriptome data. A closer inspection of the position c.80 in Integrative Genomics Viewer (IGV) (Robinson et al. 2011), revealed split and clipped reads directly connecting the end of exon 2 with a region within exon 3 of *SUPT7L*, indicating aberrant splicing at this position so that the alteration at position c.80 is intronic and spliced out (Fig. 2A, Supplementary Fig. 2B and 2C).

Using RT-PCR and direct sequencing of the obtained PCR products after gel extraction we found both transcript variants to be stable (Fig. 2B, Supplementary Fig. 2D). In addition, using qRT-PCR and the analysis of *SUPT7L* gene expression in the transcriptome data revealed on average no strong difference in comparison to controls (Supplementary Fig. 3A and 3B). The aberrant transcript generated by exon truncation lacks 67 nucleotides (NM_014860.3:r.14_82del) and is predicted to result in a frameshift p.(Arg5fs43*). Of note, also using this technique, the alteration c.80G>A was not detectable on cDNA from dermal fibroblasts. These data show that both compound heterozygous *SUPT7L* variants detected in the affected individual lead to a frameshift and thereby very likely cause a complete loss of function (Fig. 2C).

SUPT7L variants lead to loss of function and affect other components of the STAGA complex

SUPT7L encodes a component of the core structural module of the STAGA complex (Martinez et al. 2001), a nuclear multifunctional protein complex that plays a role in various cellular processes, such as transcription factor binding, protein acetylation and splicing (Supplementary Fig. 4) (Souloglou et al. 2005).

To further investigate the pathogenicity of the observed variants we performed immunolabeling in fixed dermal fibroblasts from unaffected individuals and found SUPT7L to be localized within the nucleus. In the proband's fibroblasts no signal was detectable indicating complete absence of the SUPT7L protein (Fig. 3A). In addition, we investigated the nuclear morphology in the proband's fibroblasts in comparison to controls. Using immunofluorescence staining of the nuclear envelope marker LAMIN A/C, no nuclear morphology changes were observed (Fig. 3A). To further investigate the impact of the *SUPT7L* variants we performed immunoblot analyses of SUPT7L and exemplary STAGA complex components. In the cells from the affected individual, SUPT7L was absent and the protein level of SUPT3H and TAF10 was strongly increased (Fig. 3B and C).

Loss of SUPT7L causes gene expression changes related to nuclear function and DNA damage

To gain further insight into the cellular consequence of SUPT7L loss of function, we analyzed the transcriptome data of individual II-1 and four unaffected controls. Geneset enrichment analysis revealed a downregulation of several gene sets associated with DNA replication, DNA repair, cell cycle and transcription (Fig. 4A, Supplementary Figs. 5–8, Supplementary Table 2).




Fig. 3 Consequences of the *SUPT7L* variants on protein level. (A) Immunofluorescence staining of SUPT7L in the nucleus. Representative images of SUPT7L (red) and nuclear envelope marker LAMIN A/C (green) in fibroblasts from individual II-1 and unaffected controls. SUPT7L is absent in II-1 cells. Scale: 20 μ m. (B) Immunoblot detection of the STAGA complex components SUPT7L, SUPT3H and TAF10 in lysates of fibroblasts from individual II-1 and unaffected controls. Note the loss of the SUPT7L protein in the proband. Increased protein levels of the STAGA complex components SUPT3H and TAF10 were detected. (C) Quantification of immunoblot analysis for STAGA components SUPT3H and TAF10. Students T-test: $P^{**}<0.01$; $P^{***}<0.001$




Fig. 4 SUPT7L loss of function causes gene expression changes and leads to an increased rate of DNA damage events. **(A)** Transcriptome analysis of fibroblasts from individual II-1 compared to unaffected controls. Shown are selected deregulated gene sets affecting DNA repair, cell cycle and transcription. Downregulated genes are shown in blue, not aberrant regulated genes in grey. The effect size represents the area under the curve, the brightness of the boxes shows the significance. **(B)** Representative images of immunofluorescent staining of DNA damage marker γ H2A.X (red) in fibroblasts from unaffected controls (B top) and proband II-1 (B bottom) under normal condition (-SUPT7L-WT) and transient overexpression of the turboGFP (tGFP) SUPT7L-WT fusion protein (+SUPT7L-WT). Nuclei are labeled by

white lines. **(C)** We quantified the percentage of cells with more than six γ H2A.X foci under normal conditions and after transient overexpression analyzed in B. Scale bar 20 μ m. Two-way ANOVA was performed; ns: not significant; $P^{***}<0.0001$. **(D)** Representative images of immunofluorescent staining of DNA damage marker γ H2A.X (red) in HeLa-WT (D top) and HeLa SUPT7L-KO (D bottom) under normal condition (-SUPT7L-WT) and transient overexpression of the turboGFP (tGFP) SUPT7L-WT fusion protein (+SUPT7L-WT). Nuclei are labeled by white lines. **(E)** We quantified the percentage of cells with more than six γ H2A.X foci under normal conditions and after transient overexpression analyzed in D. Scale bar 20 μ m. Two-way ANOVA was performed; ns: not significant; $P^{***}<0.0001$

Due to the lack of a second proband, we generated SUPT7L KO HeLa cells using CRISPR/Cas9 to verify our findings in a model system (Weidenfeld et al. 2009; Ran et al. 2013) (Supplementary Fig. 1). First, we wanted to know whether the proband-derived and the genome-edited cells show altered proliferation. To analyze cell proliferation, we

used the WST-1 cell proliferation assay which showed a slight reduction of proliferation rate; however, this was not significant (Supplementary Fig. 9A and 9B).

According to expression data and because the human STAGA complex is a chromatin-acetylating transcriptional coactivator associated with DNA damage binding

factors (Martinez et al. 2001; Liu et al. 2008; Gamper and Roeder 2008; Gamper et al. 2009), we investigated DNA damage levels. In both cell models, we quantified the number of DNA damage events through immunofluorescence staining using a γ H2A.X antibody (Paull et al. 2000). Approximately 19% of control fibroblasts showed more than six γ H2A.X foci compared to 37% of the proband's cells corresponding to an increase of 1.9-fold (Fig. 4B and C, Supplementary Fig. 10A). In addition, we also found an accumulation of DNA damage in the genome edited HeLa cells. Whereas 19% of the WT HeLa cells had over six γ H2A.X foci, in the SUPT7L-KO line about 51% of the cells were above this threshold corresponding to a 2.7-fold increase (Fig. 4D and E, Supplementary Fig. 10B). Therefore, the SUPT7L KO model recapitulates the increased rate of DNA damage in the proband fibroblasts and corroborates that the loss of SUPT7L leads to problems with DNA repair.

Overexpression of wild-type SUPT7L corrects elevated DNA damage

Next, we investigated whether a complementation with SUPT7L-WT would rescue this cellular phenotype. We transfected a plasmid carrying the wild type cDNA of SUPT7L in frame to a turboGFP into the proband's fibroblasts and cells from unaffected controls, as well as in the SUPT7L-KO and -WT HeLa cells. 48 h post transfection, no changes were observed in the control cells, whereas the percentage of cells with more than six γ H2A.X foci was reduced by approximately 95% in the proband's fibroblasts (Fig. 4B and C, Supplementary Fig. 10C). A similar effect was seen in the SUPT7L-KO HeLa cells where the rescue effect was 81% (Fig. 4D and E, Supplementary Fig. 10C). There was no significant difference between the transfected proband's fibroblasts and non-transfected control cells. Thus, heterologous overexpression of SUPT7L-WT completely rescued the cellular phenotype of both II-1 fibroblast and HeLa SUPT7L-KO cells.

Discussion

In the present study we describe an individual with systemic lipodystrophy leading to a progeroid appearance and severe developmental delay resembling WDRTS in many aspects. The cardinal features of WDRTS are IUGR and a postnatal failure to thrive. The affected individuals often show a dysmorphic facial gestalt including a triangular face with a prominent forehead, widely spaced eyes with downslanting palpebral fissures and deeply set ears. Further characteristics of WDRTS include hypotrichosis with sparse scalp hair, eyebrows and eyelashes, congenital cataracts, delayed

closure of the large fontanelle, a neonatal tooth, a prominent abdomen, long fingers, a prominent venous network and translucent skin due to a systemic lipodystrophy. Most of these features were also present in the here described individual, supporting the initial clinical diagnosis of WDRTS. Endocrinological and metabolic changes can also occur in WDRTS, but are more characteristic for Berardinelli-Seip congenital lipodystrophy conditions. There is also significant overlap with features of FPS in the herein described affected individual, although craniosynostosis was absent. However, no variants in the genes associated with the discussed differential diagnoses were detected neither by ES nor GS. Interestingly, the phenotypic presentation of progeroid disorders is not always suggestive for a specific genetic defect (Schnabel et al. 2021). In several cases, the diagnosis made after detection of the molecular defect differs from the initial clinical diagnosis. Many individuals with WDRTS carry causative variants in *POLR3A* and *POLR3B*, however, also pathogenic variants in *PYCR1*, *COL1A1* and other disease genes can cause overlapping conditions leading to the clinical diagnosis of WDRTS (Dimopoulou et al. 2013; Lessel et al. 2018; Paolacci et al. 2018; Wambach et al. 2018). In the affected individual described here, no pathogenic variants in the known disease genes associated with lipodystrophy or progeroid disorders were identified. Therefore, our finding adds *SUPT7L* as a novel candidate gene for progeroid conditions.

Both *SUPT7L* variants lead to the loss of the protein. Beside a clear frameshift variant, a predicted missense variant was found to be actually leading to a frameshift by exon truncation due to aberrant splicing. In the literature varying numbers are given how many missense or nonsense variants cause alternative splicing. However, it is estimated that this might affect at least 2% of missense or nonsense variants (Dufner-Almeida et al. 2019; Haque et al. 2024). The finding that a predicted missense variant causes aberrant splicing and converts a potentially stable but functionally altered product into a clear LoF is of importance for variant interpretation in general. However, aberrant splicing can also cause the generation of a stable isoform due to the formation of a cryptic splice site modulating disease severity (Kornak et al. 2022). In light of this work, one might speculate that the aberrant splicing induced by the *SUPT7L* variant c.80G>A might show tissue-specific differences. Indeed, AbSplice predicted the highest usage of the newly formed splice acceptor site in fat tissue, which is well in line with lipodystrophy phenotype (Wagner et al. 2023). Tissue with less usage of this splice site could produce the p.(Arg27Gln) isoform, which might be an explanation for the survival of the affected individual. This shows on the one hand that for all variants a potential effect on splicing should always be considered during the variant interpretation process. On the other hand, the identification of

tissue specific impacts of cryptic splice sites can be an explanation for phenotypic variability.

The identified variants led to a complete loss of function of *SUPT7L* encoding a component of the STAGA complex. We found the protein absent in fibroblasts and *SUPT7L*-KO HeLa cells using immunolabeling and immunoblots, which also demonstrates the specificity of the antibody. In addition, the absence of *SUPT7L* leads to a compensatory upregulation of other components of the STAGA complex in the proband's fibroblasts, but not in *SUPT7L*-KO HeLa cells. This is in line with previous studies showing that the depletion of *SUPT7L* does not cause such an upregulation of other complex components as found in the proband's dermal fibroblasts (Liu et al. 2008). This difference between fibroblasts and HeLa cells might be due to the intrinsically high *MYC* expression in HeLa cells, probably due to an HPV insertion, or just because of the generally aberrant character of HeLa cells (Shen et al. 2017). We currently think that a loss of *SUPT7L* results in an impairment of the STAGA complex integrity and activity, but further research is necessary to fully understand the consequences of the described variants.

Transcriptome sequencing of the proband-derived fibroblasts revealed strong alterations of gene sets encoding proteins related to DNA repair, cell cycle and the *MYC*-related transcriptional network. In addition, the STAGA complex components TAF5L and TAF6L have also been described to interact with the *c-myc* network (Seruggia et al. 2019). *MYC* is a sequence-specific transcription factor (proto-oncogene) regulating about 15% of human genes and influences chromatin structure via the recruitment of histone acetyltransferase complexes (Yamada et al. 2004; Dang et al. 2006). The recruitment of the STAGA components TRRAP and GCN5 occurs via the direct interaction of the N-terminal activation/transformation domain of *MYC* with the STAGA complex (Liu et al. 2003). This leads to hyperacetylation at specific *MYC*-dependent genes causing an increased expression. Therefore, and according to the presented data, we speculate that loss of *SUPT7L* leads to a dysfunction of the STAGA complex and thereby to alteration of *MYC*-dependent gene regulation in fibroblasts. Although this effect may vary in other cell types, potentially due to an abovementioned variable presence of a hypomorphic *SUPT7L* isoform, the consequence of *MYC* misregulation can be more mitotic errors (Topham et al. 2015). This might also be an explanation for the fact that not more individuals with this kind of defect have been identified so far. A stronger downregulation of genes from the affected pathways is unlikely to be compatible with life. Furthermore, the strong downregulation of genes related to DNA repair are in line with the known association of the human STAGA complex associated with DNA damage binding factors on protein level (Martinez et al. 2001; Liu et al. 2008; Gamper and Roeder 2008; Gamper

et al. 2009). Accordingly, we found significantly more DNA damage in the cells from the affected individual and in the genome-edited HeLa cells. The fact that this was correctable by the complementation with wild type *SUPT7L* underlines the causality of both variants and a direct involvement of this complex in DNA damage recognition.

In conclusion, we present the phenotype of an individual with a severe multisystem progeroid condition caused by pathogenic *SUPT7L* variants. We suggest *SUPT7L* as a candidate gene for conditions with systemic lipodystrophy. In addition, these data imply *SUPT7L* and the STAGA complex to be important for the regulation of DNA damage control and shows that this gene is important for normal development in humans.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00439-024-02669-y>.

Acknowledgements We thank the family for their contribution to our work. UK received funding from ERA-Net for Research on Rare Diseases (KO2891/6-1; EUROGLYCAN-omics), and the Deutsche Forschungsgemeinschaft (DFG) Research Unit FOR 2165. BF-Z was supported by a grant from the DFG (FI 2240/1-1). This work was supported by the DFG Research Infrastructure West German Genome Center (project 407493903) as part of the Next Generation Sequencing Competence Network (project 423957469). NGS analyses were carried out at the production site Cologne (Cologne Center for Genomics (CCG)). [BF-Z as co-PI] received the DFG grant 458854948 as part of the DFG Sequencing call 3. This work was supported by the Case Analysis and Decision Support (CADS) program of the Berlin Institute of Health at Charité – Universitätsmedizin Berlin.

Author contributions J.K., U.K., B.F.-Z.; designed the study. J.K., L.A.K., H.L., O.K., C.D., E.L., S.B., D.S., N.E., U.K., M.F., B.F.-Z.; performed experiments and were involved in data analysis. M.H., O.K., A.I., contributed bioinformatics analysis. U.K., N.E., M.F.; contributed with clinical evaluation of the case. U.K., S.M., B.F.-Z.; provided resources. J.K., L.A.K., H.L., B.F.-Z.; were involved in visualization. J.K., B.F.-Z wrote the original draft. All authors critical revised the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL.

Data availability No datasets were generated or analysed during the current study.

Declarations

Ethics approval The Charité - Universitätsmedizin Berlin ethics committee approved the study (EA2/145/07). All procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 2000.

Consent to participate The parents of the affected individual II-1 provided written consent for genetic testing and the publication of images in Fig. 1.

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Adzhubei I, Jordan DM, Sunyaev SR (2013) Predicting functional effect of human missense mutations using PolyPhen-2. *Curr Protoc Hum Genet Chap. 7:Unit7.20*
- Baux D, Van Goethem C, Ardouin O et al (2021) MobiDetails: online DNA variants interpretation. *Eur J Hum Genet* 29:356–360
- Dang CV, O'Donnell KA, Zeller KI et al (2006) The c-Myc target gene network. *Semin Cancer Biol* 16:253–264
- De Sandre-Giovannoli A, Bernard R, Cau P et al (2003) Lamin a truncation in Hutchinson-Gilford progeria. *Science* 300:2055
- DePristo MA, Banks E, Poplin R et al (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 43:491–498
- Dimopoulou A, Fischer B, Gardeitchik T et al (2013) Genotype-phenotype spectrum of PYCR1-related autosomal recessive cutis laxa. *Mol Genet Metab* 110:352–361
- Dobin A, Davis CA, Schlesinger F et al (2013) STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29:15–21
- Dufner-Almeida LG, do Carmo RT, Masotti C, Haddad LA (2019) Understanding human DNA variants affecting pre-mRNA splicing in the NGS era. *Adv Genet* 103:39–90
- Eriksson M, Brown WT, Gordon LB et al (2003) Recurrent de novo point mutations in lamin a cause Hutchinson-Gilford progeria syndrome. *Nature* 423:293–298
- Gamper AM, Roeder RG (2008) Multivalent binding of p53 to the STAGA complex mediates coactivator recruitment after UV damage. *Mol Cell Biol* 28:2517–2527
- Gamper AM, Kim J, Roeder RG (2009) The STAGA subunit ADA2b is an important regulator of human GCN5 catalysis. *Mol Cell Biol* 29:266–280
- Haque B, Cheerie D, Birkadze S, et al (2024) Estimating the proportion of nonsense variants undergoing the newly described phenomenon of manufactured splice rescue. *Eur J Hum Genet* 32:238–242
- Henning KA, Li L, Iyer N et al (1995) The Cockayne syndrome group A gene encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH. *Cell* 82:555–564
- Hirsch CL, Coban Akdemir Z, Wang L et al (2015) Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming. *Genes Dev* 29:803–816
- Holtgrewe M, Stolpe O, Nieminen M et al (2020) VarFish: comprehensive DNA variant analysis for diagnostics and research. *Nucleic Acids Res* 48:W162–W169
- Jäger M, Wang K, Bauer S et al (2014) Jannovar: a java library for exome annotation. *Hum Mutat* 35:548–555
- Jéru I (2021) Genetics of lipodystrophy syndromes. *Presse Med* 50:104074
- Karczewski KJ, Francioli LC, Tiao G et al (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 581:434–443
- Kircher M, Witten DM, Jain P et al (2014) A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 46:310–315
- Kornak U, Saha N, Keren B et al (2022) Alternative splicing of BUD13 determines the severity of a developmental disorder with lipodystrophy and progeroid features. *Genet Med* 24:1927–1940
- Lessel D, Kubisch C (2019) Hereditary syndromes with signs of premature aging. *Dtsch Arztebl Int* 116:489–496
- Lessel D, Ozel AB, Campbell SE et al (2018) Analyses of LMNA-negative juvenile progeroid cases confirms biallelic POLR3A mutations in Wiedemann-Rautenstrauch-Like syndrome and expands the phenotypic spectrum of PYCR1 mutations. *Hum Genet* 137:921–939
- Liao Y, Smyth GK, Shi W (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 30:923–930
- Liu X, Tesfai J, Evrard YA et al (2003) c-Myc transformation domain recruits the human STAGA complex and requires TRRAP and GCN5 acetylase activity for transcription activation. *J Biol Chem* 278:20405–20412
- Liu X, Vorontchikhina M, Wang Y-L et al (2008) STAGA recruits Mediator to the MYC oncoprotein to stimulate transcription and cell proliferation. *Mol Cell Biol* 28:108–121
- Love MI, Huber W, Anders S (2014) Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15:550
- Martinez E, Palhan VB, Tjernberg A et al (2001) Human STAGA complex is a chromatin-acetylating transcription coactivator that interacts with pre-mRNA splicing and DNA damage-binding factors in vivo. *Mol Cell Biol* 21:6782–6795
- McKenna A, Hanna M, Banks E et al (2010) The genome analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 20:1297–1303
- Nagy Z, Riss A, Romier C et al (2009) The human SPT20-containing SAGA complex plays a direct role in the regulation of endoplasmic reticulum stress-induced genes. *Mol Cell Biol* 29:1649–1660
- Nolis T (2014) Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. *J Hum Genet* 59:16–23
- Paolacci S, Li Y, Agolini E et al (2018) Specific combinations of biallelic *POLR3A* variants cause Wiedemann-Rautenstrauch syndrome. *J Med Genet* 55:837–846
- Paull TT, Rogakou EP, Yamazaki V et al (2000) A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. *Curr Biol* 10:886–895
- Ran FA, Hsu PD, Wright J et al (2013) Genome engineering using the CRISPR-Cas9 system. *Nat Protoc* 8:2281–2308
- Robinson JT, Thorvaldsdóttir H, Winckler W et al (2011) Integrative genomics viewer. *Nat Biotechnol* 29:24–26
- Schnabel F, Kornak U, Wollnik B (2021) Premature aging disorders: a clinical and genetic compendium. *Clin Genet* 99:3–28
- Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods* 11:361–362
- Sepehri S, Hernandez N (1997) The largest subunit of human RNA polymerase III is closely related to the largest subunit of yeast and trypanosome RNA polymerase III. *Genome Res* 7:1006–1019
- Seruggia D, Oti M, Tripathi P et al (2019) TAF5L and TAF6L maintain Self-Renewal of embryonic stem cells via the MYC Regulatory Network. *Mol Cell* 74:1148–1163e7
- Shen C, Liu Y, Shi S et al (2017) Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region upregulating the allele-specific MYC expression in HeLa cells. *Int J Cancer* 141:540–548
- Sobreira N, Schiettecatte F, Valle D, Hamosh A (2015) GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum Mutat* 36:928–930

- Soutoglou E, Demény MA, Scheer E et al (2005) The nuclear import of TAF10 is regulated by one of its three histone Fold domain-containing interaction partners. *Mol Cell Biol* 25:4092–4104
- Switonski PM, Delaney JR, Bartelt LC et al (2021) Altered H3 histone acetylation impairs high-fidelity DNA repair to promote cerebellar degeneration in spinocerebellar ataxia type 7. *Cell Rep* 37:110062
- Tan JY, Vance KW, Varela MA et al (2014) Cross-talking noncoding RNAs contribute to cell-specific neurodegeneration in SCA7. *Nat Struct Mol Biol* 21:955–961
- Thomas MC, Chiang C-M (2006) The general transcription machinery and general cofactors. *Crit Rev Biochem Mol Biol* 41:105–178
- Topham C, Tighe A, Ly P et al (2015) MYC is a major determinant of mitotic cell fate. *Cancer Cell* 28:129–140
- Wagner N, Çelik MH, Hölzlwimmer FR et al (2023) Aberrant splicing prediction across human tissues. *Nat Genet* 55:861–870
- Wambach JA, Wegner DJ, Patni N et al (2018) Bi-allelic POLR3A loss-of-function variants cause autosomal-recessive Wiedemann-Rautenstrauch Syndrome. *Am J Hum Genet* 103:968–975
- Weidenfeld I, Gossen M, Löw R et al (2009) Inducible expression of coding and inhibitory RNAs from retargetable genomic loci. *Nucleic Acids Res* 37:e50–e50
- Woods CG (2004) Human microcephaly. *Curr Opin Neurobiol* 14:112–117
- Wu S-W, Li L, Feng F et al (2021) Whole-exome sequencing reveals POLR3B variants associated with progeria-related Wiedemann-Rautenstrauch syndrome. *Ital J Pediatr* 47:160
- Yamada T, Mizuno K-I, Hirota K et al (2004) Roles of histone acetylation and chromatin remodeling factor in a meiotic recombination hotspot. *EMBO J* 23:1792–1803
- Yu CE, Oshima J, Fu YH et al (1996) Positional cloning of the Werner's syndrome gene. *Science* 272:258–262
- Zhang N, Ichikawa W, Faiola F et al (2014) MYC interacts with the human STAGA coactivator complex via multivalent contacts with the GCN5 and TRRAP subunits. *Biochim Biophys Acta* 1839:395–405
- Zhao Y, Lang G, Ito S et al (2008) A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. *Mol Cell* 29:92–101
- Zyla J, Marczyk M, Domaszewska T et al (2019) Gene set enrichment for reproducible science: comparison of CERNO and eight other algorithms. *Bioinformatics* 35:5146–5154

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Johannes Kopp^{1,2,3} · Leonard A. Koch¹ · Hristiana Lyubenova^{1,2} · Oliver Küchler^{1,4} · Manuel Holtgrewe⁵ · Andranik Ivanov⁵ · Christele Dubourg^{6,7} · Erika Launay⁸ · Sebastian Brachs^{9,10} · Stefan Mundlos^{1,2} · Nadja Ehmke^{1,11} · Dominik Seelow^{1,4} · Mélanie Fradin^{12,13} · Uwe Kornak^{1,2,14} · Björn Fischer-Zirnsak^{1,2}

✉ Björn Fischer-Zirnsak
bjoern.fischer@charite.de

¹ Institute of Medical Genetics and Human Genetics, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, 13353 Berlin, Germany

² Max Planck Institute for Molecular Genetics, FG Development and Disease, Berlin, Germany

³ Institute of Chemistry and Biochemistry, Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Berlin, Germany

⁴ Exploratory Diagnostic Sciences, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Berlin, Germany

⁵ Core Unit Bioinformatics (CUBI), Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Berlin, Germany

⁶ Service de Génétique Moléculaire et Génomique, CHU, Rennes F-35033, France

⁷ University Rennes, CNRS, INSERM, IGDR, UMR 6290, ERL U1305, Rennes F-35000, France

⁸ Service de Cytogénétique et Biologie cellulaire, Hôpital Pontchaillou - CHU Rennes, 2 rue Henri Le Guilloux – Rennes cedex 9, France, Rennes F-35033, France

⁹ Department of Endocrinology and Metabolism, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany

¹⁰ German Centre for Cardiovascular Research, partner site Berlin, Berlin, Germany

¹¹ Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Berlin, Germany

¹² Service de Génétique Clinique, Centre Référence Déficiences Intellectuelles CRDI, Hôpital Sud - CHU Rennes, 16 boulevard de Bulgarie - BP 90347, Rennes cedex 2, Rennes F-35203, France

¹³ Service de Génétique, CH Saint Briec, St Briec 22000, France

¹⁴ Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany